Patents by Inventor Dalian Zhao

Dalian Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190185414
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Application
    Filed: January 11, 2019
    Publication date: June 20, 2019
    Inventors: Raymond E. STEVENS, Dalian ZHAO, Bingidimi Itute MOBELE
  • Patent number: 10221126
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: March 5, 2019
    Assignee: VELICEPT THERAPEUTICS, INC.
    Inventors: Raymond E. Stevens, Dalian Zhao, Bingidimi Itute Mobele
  • Publication number: 20180370902
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Application
    Filed: June 26, 2018
    Publication date: December 27, 2018
    Inventors: Raymond E. STEVENS, Dalian ZHAO, Bingidimi Itute MOBELE
  • Patent number: 10065922
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: September 4, 2018
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Raymond E. Stevens, Dalian Zhao, Bingidimi Itute Mobele
  • Publication number: 20170114005
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Application
    Filed: October 24, 2016
    Publication date: April 27, 2017
    Inventors: Raymond E. STEVENS, Dalian ZHAO, Bingidimi Itute MOBELE
  • Publication number: 20100292282
    Abstract: The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methyl-propyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.
    Type: Application
    Filed: October 20, 2008
    Publication date: November 18, 2010
    Inventors: Kevin R. Campos, Cheng-Yi Chen, Jennifer R. Foley, Michael Hillier, Wendy S. Jen, Amude M. Kassim, Artis Klapars, Andrey V. Peresypkin, Thorsten Rosner, Cecile G. Savarin, Matthew Tudge, Narayan Variankaval, Vicky Vydra, Dalian Zhao
  • Patent number: 7683092
    Abstract: Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: March 23, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dalian Zhao, Jean-Francois Marcoux, David Boardman, Aquiles E. Leyes
  • Publication number: 20080221198
    Abstract: Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.
    Type: Application
    Filed: March 10, 2006
    Publication date: September 11, 2008
    Inventors: Dalian Zhao, Jean-Francois Marcoux, David Boardman, Aquiles E. Leyes
  • Patent number: 6281391
    Abstract: This invention encompasses a novel process for synthesizing compounds represented by formula A: These compounds are intermediates useful in the preparation of certain agents that are selective COX-2 inhibitors.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: August 28, 2001
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Richard D. Tillyer, Ian W. Davies, Robert D. Larsen, Xin Wang, Paul O'Shea, Anthony On-Ping King, Dalian Zhao, Cheng Y. Chen, Edward J. J. Grabowski
  • Patent number: 6040480
    Abstract: The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxazin-2-one of formula (VI-i) ##STR1## which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: March 21, 2000
    Assignee: Du Pont Pharmaceuticals Company
    Inventors: Michael E. Pierce, Cheng Y. Chen, Anusuya Choudhury, Lilian A. Radesca, Lushi Tan, Dalian Zhao
  • Patent number: 5925789
    Abstract: The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxazin-2-one of formula (VI-i) ##STR1## which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: July 20, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Michael E. Pierce, Cheng Y. Chen, Anusuya Choudhury, Lilian A. Radesca, Lushi Tan, Dalian Zhao
  • Patent number: 5856492
    Abstract: An efficient method for the quantitative preparation and isolation of a compound of formula I ##STR1## or its enantiomer, a chiral mediator used in enantioselective synthesis.
    Type: Grant
    Filed: January 5, 1998
    Date of Patent: January 5, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Cheng Yi Chen, Feng Xu, Richard D. Tillyer, Dalian Zhao
  • Patent number: 5792871
    Abstract: Compound 9 is prepared by a 9-step ##STR1## process in an overall yield of about 35% from 3-acetylpyridine. Compound 10 is prepared by a seven-step ##STR2## process in an overall yield of about 30% from 3-acetyl pyridine. These compounds are key intermediates in the synthesis of Compound 11, an important .beta.-3 agonist useful in the treatment of obesity and diabetes.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: August 11, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Michel M. Chartrain, Christopher Roberge, John Y. L. Chung, Dalian Zhao
  • Patent number: 5686607
    Abstract: The invention is a highly efficient synthesis for making compounds of formula (iv) wherein R is C.sub.1-4 alkyl or benzyl; and R.sup.1, when present, is C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl, or S--C.sub.1-4 alkyl; which are useful intermediates for making compounds such as those represented in formula (I).
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: November 11, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John Y. L. Chung, Dalian Zhao, David J. Mathre
  • Patent number: 5665882
    Abstract: The invention is a highly efficient synthesis for making compounds of formula: ##STR1## wherein n=0, 1, R is C.sub.1-4 alkyl or benzyl; andR.sup.1, when present, is C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl or S--C.sub.1-4 alkyl. The process involves silane-mediated conjugation of 4-vinylpyridine to a substituted lactam.
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: September 9, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John Y. L. Chung, Dalian Zhao, James M. McNamara, David L. Hughes
  • Patent number: 5312923
    Abstract: The invention is a highly efficient synthesis for making compounds of the formula: ##STR1## wherein: R.sup.1 is a six membered saturated or unsaturated heterocyclic ring containing one or two heteroatoms wherein the heteroatoms are N; or NR.sup.6, wherein R.sup.6 is H or C.sub.1-10 alkyl;m is an integer from two to six; andR.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl.
    Type: Grant
    Filed: February 16, 1993
    Date of Patent: May 17, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John Y. L. Chung, David L. Hughes, Dalian Zhao
  • Patent number: 5274096
    Abstract: An improved synthesis is described for producing a quinolinylmethoxyphenyl hydrazine which is an intermediate in the preparation of quinolinylmethoxyindoles useful as inhibitors of leukotriene biosynthesis. The improved process eliminates two isolation steps and yields a product of high purity.
    Type: Grant
    Filed: March 17, 1992
    Date of Patent: December 28, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Joseph F. Payack, Dalian Zhao
  • Patent number: 5206373
    Abstract: The invention is a highly efficient synthesis for making compounds of the formula: ##STR1## wherein: R.sup.1 is a six member saturated or unsaturated heterocyclic ring containing one or two heterocyclic atoms wherein the heteroatoms are N; or NR.sup.6, wherein R.sup.6 is H or C.sub.1-10 alkyl;m is an integer from two to six; andR.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl.
    Type: Grant
    Filed: February 28, 1992
    Date of Patent: April 27, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John Y. L. Chung, David L. Hughes, Dalian Zhao
  • Patent number: 5157122
    Abstract: An indole having the formula I: ##STR1## is prepared by a Fischer-Indole reaction employing a mixture of phosphorous pentoxide and methane sulfonic acid as an acid catalyst. The reaction, which is optionally run in a co-solvent, provides 3-unsubstituted indoles in high yields with high regioselectivity. The indole thus prepared is an intermediate in the synthesis of leukotriene biosynthesis inhibitors.
    Type: Grant
    Filed: January 18, 1991
    Date of Patent: October 20, 1992
    Assignee: Merck & Co., Inc.
    Inventors: David L. Hughes, Dalian Zhao